Fig. 6

In vivo safety and bone protection of Bm@PT/Enz-miR26a in two models. (A–B) The H&E images of heart, liver, spleen, lung, kidney, tumor, and bone (left hind limb tibia) of each group in (A) subcutaneous CRPC and (B) BmCRPC mouse models. Scale bar: 100 μm. Red arrow: tumor metastatic sites. (C–D). The biochemical analysis of mouse blood samples in (C) subcutaneous CRPC and (D) BmCRPC mouse models. n = 3, mean ± SD. (E) Metastasis in the heart and lungs of tumor-bearing mice in BmCRPC model. Yellow circle: tumor. (F) The micro-CT images of each group in the BmCRPC mouse model. n = 5, red arrows: bone damaged sites. (G–H) The miR26a level of each group in (G) subcutaneous CRPC and (H) BmCRPC mouse models. n = 3, mean ± SD, ****p < 0.0001, one-way ANOVA. (I–J) Related protein expressions of each group in (I) subcutaneous CRPC and (J) BmCRPC mouse models. (K) Immunofluorescence results of each group in subcutaneous CRPC model. Scale bar: 20 μm. (L) Immunofluorescence results of each group in the BmCRPC mouse model. Scale bar: 20 μm. (M) Mean fluorescence intensity in subcutaneous CRPC model. n = 3, mean ± SD, ****p < 0.0001, one-way ANOVA. (N) Mean fluorescence intensity in BmCRPC mouse model. n = 3, mean ± SD, ****p < 0.0001, one-way ANOVA